Response of KIT transduced Ba/F3 cells to selective PTK inhibitors
. | IC50, μM . | . | . | ||
|---|---|---|---|---|---|
. | Imatinib . | PD98059 . | LY294002 . | ||
| KIT-WT | 0.07 | 6.0 | 1.5 | ||
| T417I/Δ418_419 | 0.05 | 8.5 | 2.5 | ||
| D816V | 3.0* | 10.0 | 2.5 | ||
| KIT-WT + IL-3 | 7.0* | > 25 | > 10 | ||
. | IC50, μM . | . | . | ||
|---|---|---|---|---|---|
. | Imatinib . | PD98059 . | LY294002 . | ||
| KIT-WT | 0.07 | 6.0 | 1.5 | ||
| T417I/Δ418_419 | 0.05 | 8.5 | 2.5 | ||
| D816V | 3.0* | 10.0 | 2.5 | ||
| KIT-WT + IL-3 | 7.0* | > 25 | > 10 | ||
Ba/F3 cells were grown in presence of 100 ng/mL SCF or 10 ng/mL IL-3 as indicated. Inhibitory concentration of 50% (IC50) values in the relevant cell lines of KIT inhibitor imatinib, MEK1 inhibitor PD98059, and Pl3-kinase inhibitor LY294002 were assessed by counting viable cells after 72 hours. Results represent means of 3 independent experiments. Final concentrations of dimethyl sulfoxide (DMSO) did not exceed 0.25%, which was nontoxic for Ba/F3 cells in control experiments. Values labeled with an asterisk were significantly different from the corresponding wild-type value.